Karen Knudsen, CEO of Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“There’s nothing better than meeting up with former trainees who are truly flourishing in their careers, and in the case of Emily E. Bosco, blazing incredible new trails at AstraZeneca for treating advanced prostate cancer.
So wonderful to spend the last several days with brilliant AZ leaders. Next stop, ASCO !”
More posts featuring ASCO25.